S Vikipedije, slobodne enciklopedije
Bevacizumab (brend Avastin , Genentek /Roš ) je monoklonsko antitelo koje se selektivno veže na protein vaskularni endotelijalni faktor rasta A (VEGFA )[ 1] krvnih i limfnih sudova .
^ Los M, Roodhart JM, Voest EE (2007). . „Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer”. The Oncologist . 12 (4): 443—50. PMID 17470687 . doi :10.1634/theoncologist.12-4-443 .
"-tuzu-" (tumor ) Afutuzumab ,
Alemtuzumab ,
Bevacizumab ,
Bivatuzumab mertansine ,
Cantuzumab mertansine ,
Citatuzumab bogatox ,
Dacetuzumab ,
Elotuzumab † ,
Etaracizumab ,
Farletuzumab ,
Gemtuzumab ozogamicin ,
Inotuzumab ozogamicin ,
Labetuzumab ,
Lintuzumab ,
Matuzumab § ,
Milatuzumab ,
Nimotuzumab ,
Oportuzumab monatox ,
Pertuzumab ,
Sibrotuzumab ,
Tacatuzumab tetraxetan ,
Tigatuzumab ,
Trastuzumab ,
Tucotuzumab celmoleukin ,
Veltuzumab "-lizu-" (imunski sistem ) imunosupresivni: Aselizumab ,
Apolizumab ,
Benralizumab † ,
Cedelizumab ,
Certolizumab pegol ,
Daclizumab ,
Eculizumab ,
Efalizumab ,
Epratuzumab ,
Erlizumab ,
Fontolizumab ,
Mepolizumab ,
Natalizumab ,
Ocrelizumab ,
Omalizumab ,
Pascolizumab ,
Pexelizumab ,
PRO 140 † ,
Reslizumab ,
Rontalizumab ,
Rovelizumab ,
Ruplizumab ,
Siplizumab ,
Talizumab ,
Teplizumab ,
Tocilizumab ,
Toralizumab ,
Vedolizumab ,
Visilizumab ,
TGN1412 § non-imunosupresivni: Ibalizumab † "-bazu-" (bakterijski ) "-cizu-" (kardiovaskularni ) "-nezu-"/"-neuzu-" (nervni sistem ) "-toksazu-" (toksin kao meta) "-vizu-" (viralni ) "-kizu-" (interleukin kao meta) "-anibizu-" (inhibitor angiogeneze )
